The vital importance of
research into technologies of
healing and peace is never more
painfully apparent than in the midst of war. On August 3,
2006, on the same day that more than 230 rockets rained
into northern Israel over the Lebanese border in one of
the heaviest barrages of Hezbollah rocket fire in the
recent war, a small package from Switzerland, ordered
and paid for by MAPS, arrived safely and legally in Tel
Aviv, Israel. Inside the package was close to five grams
of pharmaceutical-grade MDMA. With the arrival of this
MDMA, the final piece of the puzzle was put into place
for our MAPS-sponsored Israeli pilot study investigating
the safety and efficacy of MDMA-assisted psychotherapy
in subjects with war- and terrorism-related posttraumatic
stress disorder (PTSD). This study is now set to
begin, just as a tragically large number of Israelis and
Lebanese have been freshly traumatized by yet another
war. The technologies of war continue to advance, yet,
more slowly and quietly, technologies of healing and
peace are also progressing.
At a recent conference in Tel-Aviv, sponsored by
the Israeli Anti-Drug Authority, one of the speakers
noted that about 20 million doses of MDMA are smuggled
into Israel each year, and “every one is a hand grenade.”
The emotionally inflamed rhetoric of the War on Drugs,
so often used to generate the fear required to justify the
harshness of prohibition, is so clearly hollow when
viewed through the lens of actual war.
The potential of MDMA-assisted psychotherapy
to become an accepted and widely-used technology
of healing is becoming more realistic, as evidenced
by Dr. Michael Mithoefer’s latest update on his US
MDMA/ PTSD study (page 6), Dr. Peter Oehen’s report
on the imminent initiation of his Swiss MDMA/PTSD
study (page 9), and MAPS Clinical Research Associate
Valerie Mojeiko’s report on the Israeli MDMA/PTSD
study (page 8). Furthermore, the recent donation to
MAPS of $250,000 by philanthropist Peter Lewis for
these three pilot studies guarantees their implementation,
which we expect will take the next two years. Then we
will be in a position to review data and decide whether
it makes scientific and financial sense to initiate the
multi-site Phase 3 studies required to obtain permission
from the FDA and the European Medicines Agency for
the prescription use of MDMA.
MAPS’ overall strategy to develop psychedelics into
prescription medicines also involves studies exploring
the use of psychedelics in treating anxiety associated
with end-of-life issues. By demonstrating the value of
psychedelics for a use that almost everyone is concerned
about, to help ease the emotional and physical pain of
dying, MAPS hopes to show that psychedelic psychotherapy
offers potential benefits to people who would
otherwise never consider taking such drugs.
MAPS is working with Swiss psychiatrist Peter Gasser,
M.D., on the design and approval process for a MAPSsponsored
study exploring the use of LSD-assisted
psychotherapy in people with anxiety dealing with endof-
life issues from cancer as well as other causes (page
10). Once approved, this study will become the first
government-approved LSD psychotherapy research in
over 35 years. This study will complement research by
John Halpern, M.D., investigating MDMA-assisted
psychotherapy in advanced-stage cancer patients (for
which MAPS coordinated the design and approval
process and which Peter Lewis is personally sponsoring)
as well as Dr. Charles Grob’s ongoing Heffter Research
Institute-sponsored study of psilocybin-assisted psychotherapy
in advanced-stage cancer patients. Dr. Carl
Hammerschlag’s case report describing the use of
ketamine-assisted psychotherapy with a terminally ill
patient (page 11) lends further support to the potential
of psychedelics as tools to assist in the dying process, and
suggests yet another promising area of research. As part
of our educational mission, MAPS is proud to have just
published Dr. Stanislav Grof’s new book, The Ultimate
Journey: Consciousness and the Mystery of Death, based
in part on his LSD research with cancer patients.
MAPS’ efforts to develop marijuana into an FDAapproved
prescription medicine are also moving forward.
Our lawsuit against the DEA for refusing to issue a license
for a MAPS-sponsored marijuana production facility is
approaching its climactic moment: the recommendation
of the Administrative Law Judge to the Administrator of
the DEA (page 3). We’re re preparing for the possibility
that the recommendation will be favorable.
At twenty years old, MAPS is going through an
exciting yet challenging growth phase. At this time
of celebration and reflection, culminating in our 20th
anniversary gathering at Burning Man, I’m deeply
grateful for the partnership of MAPS members and staff,
which has made this all possible. Working together, we
can accomplish even the seemingly impossible–the end
of the Drug War and the legalization of psychedelic
technologies of peace and healing.
– Rick Doblin, Ph.D., MAPS President
|